Malignant Disease

Overview

Malignant disease refers to a class of disorders characterized by the uncontrolled growth, invasion, and spread of abnormal cells, most commonly used in biomedical contexts to denote cancer and malignant tumors. Biologically, malignant disease is defined by the capacity of transformed cells to evade normal growth control, resist cell death, remodel surrounding tissue, and metastasize to distant sites. These properties make malignant disease a major cause of morbidity and mortality worldwide and a central focus of oncology, immunology, molecular biology, and translational medicine.

In recent research, malignant disease has been studied not only as a clinical endpoint but also as a therapeutic target for precision oncology, immunotherapy, gene editing, and nanomedicine. Investigations frequently intersect with tumor microenvironment biology, checkpoint inhibitor, T-lymphocytes, natural killer (NK) cells, dendritic cell targeting, STING1 signaling, toll-like receptor pathways, and mitochondrial dysfunction. The term also appears in broader disease frameworks linking cancer with oxidative stress, chronic inflammation, metabolic dysfunction–associated steatotic liver disease, cardiovascular disease, and other age-related disorders.

Focus of Latest Publications

Recent publications show malignant disease being addressed across a wide range of therapeutic and diagnostic strategies, with cancer and malignant tumors serving as the principal biological context.

Several studies focused on immunotherapy. A review of bispecific T cell engagers and higher-order multispecific immunotherapeutics described engineered antibodies that redirect immune effector cells toward tumor targets, thereby eliciting coordinated antitumor immune responses. Other work examined immune checkpoint inhibitors, noting that these agents have transformed cancer treatment by enhancing antitumor immunity, although durable responses occur in only a fraction of patients. Related publications discussed vaccine safety in individuals receiving immune checkpoint inhibitor therapy and the use of pneumococcal conjugate vaccines in children with cancer or other immunocompromising conditions, reflecting the clinical overlap between malignant disease and immune modulation. Additional studies explored dendritic cell targeting, dendritic cell extracellular vesicles, and lipid-based delivery systems for dendritic cell targeting as platforms for more effective and durable cancer immunotherapies.

Cell-based and receptor-engineered therapies were also prominent. Research on chimeric antigen receptor (CAR) approaches included edited CAR-T cells with enhanced cytotoxicity and complete tumor clearance in vivo, as well as work on affinity tuning to balance efficacy and safety by reducing cytokine release syndrome. A separate study on TIGIT base editing in natural killer cells showed that TIGIT BE-NK cells specifically targeted cancer cells across multiple tumor types and were validated as safe with minimal off-target effects. These findings align with broader efforts to improve immune cell specificity against malignant disease while limiting toxicity.

Multiple publications addressed molecular and pathway-level mechanisms relevant to malignant disease. Reviews and computational studies highlighted apoptosis evasion, the apoptosis-pyroptosis transition, ER stress adaptation, extracellular matrix remodeling, and metastasis. Matrix metalloproteinase-2 (MMP-2) was described as a key mediator of extracellular matrix remodeling and cancer metastasis. Other studies examined cuproptosis-mediated cancer therapy, STING agonists, TLR7/8 modulators, and CRISPR-based epigenetic editing, all of which reflect attempts to manipulate signaling and regulatory networks that support malignant progression. Mitochondrial dysfunction and mitochondria-organelle collaboration were also discussed as disease-relevant processes, with cancer included among the major pathological conditions linked to these mechanisms.

Nanotechnology and targeted delivery were recurring themes. Publications described bioresponsive nanomedicines, metal-organic framework-based drug delivery systems, lipid nanoparticles, nanobody-based Targeted Cancer Therapy, and polysaccharide/lipid composite nanovesicles for precision cancer therapy. These platforms were presented as ways to improve tumor accumulation, reduce systemic off-target effects, and enhance delivery of drugs, genes, proteins, or photosensitizers. Sonodynamic therapy and gas therapy were also reviewed as combinatorial strategies for malignant tumors, illustrating the continued search for multimodal treatment approaches.

Diagnostic and prognostic research was equally active. Early-stage oncology diagnosis was emphasized as critical for improving survival, quality of life, and health system efficiency. AI-driven imaging, precision oncology, tumor-only variant calling, mutation burden estimation, and multi-omics biomarker studies were all used to improve detection, stratification, and treatment planning. One study on baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy underscored the ongoing effort to identify biomarkers that can forecast response to therapy. Another publication on global burden of cancer in children and adolescents highlighted the importance of epidemiologic data for cancer policy planning.

The literature also reflects the broad clinical and psychosocial impact of malignant disease. Studies on cancer care coordination, patient perceptions of care team selection, mobile sensor data integration, and the bidirectional relationship between cancer and depression show that malignant disease affects not only tumor biology but also care delivery, mental health, and health-system organization. In addition, work on cadmium-related lung toxicity and carcinogenesis, CKM syndrome severity as a risk factor for cancer, and childhood cancer burden demonstrates that malignant disease is studied in relation to environmental exposures, metabolic risk, and population-level outcomes.

Key Publications

• Jun Transoral endoscopic approach to skull base lesions: A 10-year experience at a single tertiary center. (Neurosurgical review, 2026, PMID 42217086): "Recurrence occurred in 14 of 38 cases of malignant tumors and in 4 of 33 cases with benign lesions."
• May "You're the person for me:" patient perceptions of cancer care team selection and experiences with care coordination within a rural hub-and-spoke health system. (Cancer causes & control : CCC, 2026, PMID 42189271): "Cancer care requires coordination across several clinical and supportive care specialties."
• May Clinician Perspectives on Integrating Mobile Sensor Data Into Cancer Care: Mixed Methods Study. (JMIR cancer, 2026, PMID 42102279): "However, limited research has been conducted on oncology provider perspectives on how these data could be used to inform cancer care."
• May From intelligent models to clinical tools: the evolving landscape of AI in medical imaging. (Scientific reports, 2026, PMID 42069740): "This Collection explores the rapid advancement of AI-driven tools in their specific fields such as oncology, cardiology, ophthalmology and so on, highlighting their potential to improve diagnostic accuracy, workflow efficiency, and personalized treatment planning."
• May Implementing AI in Radiotherapy: Insights From the Healthcare Professions. (Sociology of health & illness, 2026, PMID 42017679): "In this study, we interviewed 32 HCPs involved in cancer treatment using these AI tools, across five different regional cancer centres in England."
• May Mapping the evolution of cell and gene therapy product research: trends, collaborations, and emerging frontiers. (Therapeutic innovation & regulatory science, 2026, PMID 41787225): "Cell and gene therapy products demonstrate considerable promise for both foundational scientific inquiry and diverse clinical interventions, with their utility now extending far beyond cancer treatment to encompass a wide array of other pathological conditions."
• May Drug development trajectory of anticancer drugs after initial pediatric-eligible trials. (Cancer, 2026, PMID 42046241): "Attrition of new therapies is a major concern in oncology drug development."
• Apr Patient and Provider Experiences With Precision Oncology: Qualitative Descriptive Study at the Department of Veterans Affairs. (JMIR cancer, 2026, PMID 42044630): "Precision oncology (PO) improves and extends the lives of patients living with cancer, but multiple studies have documented its underuse in practice."
• Apr Design and Synthesis of New Pyrazolo[1,5-c]quinazolin-5-amines as Potential TLR7/8 Modulators. (ChemMedChem, 2026, PMID 42014047): "TLR7 and 8 agonists are potentially valuable vaccine adjuvants while antagonists show useful activity against autoimmune diseases and cancer."
• Apr Artificial intelligence-based screening of phytochemicals for targeted cancer therapy. (Natural products and bioprospecting, 2026, PMID 42012749): "Cancer remains one of the leading causes of death worldwide and continues to pose a serious public health challenge."